Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma.
about
Generation and comparison of CRISPR-Cas9 and Cre-mediated genetically engineered mouse models of sarcoma.Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade.Recombinant cells in the lung increase with age via de novo recombination events and clonal expansion.Driver genes in non-small cell lung cancer: Characteristics, detection methods, and targeted therapies.EGFR mutation, smoking, and gender in advanced lung adenocarcinoma.Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy.Kras mutant genetically engineered mouse models of human cancers are genomically heterogeneous.CDK4/6 Inhibition Augments Anti-Tumor Immunity by Enhancing T Cell Activation.Lung Endothelial MicroRNA-1 Regulates Tumor Growth and Angiogenesis.Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities.MYC and RAF: Key Effectors in Cellular Signaling and Major Drivers in Human Cancer.Modeling Genomic Instability and Selection Pressure in a Mouse Model of Melanoma.and effects of hyperplasia suppressor gene on the proliferation and apoptosis of lung adenocarcinoma A549 cellsMouse models in the era of large human tumour sequencing studiesAutochthonous murine models for the study of smoker and never-smoker associated lung cancers
P2860
Q33899910-551AFA58-8ADB-497C-B284-6F39909CF13EQ38707904-B22DE27B-EF90-4D5F-BB98-9ACE4EF18262Q40267141-51150133-AC15-4BAA-86B1-49B73B832ED8Q41340094-2F3306A9-9F2D-4125-B4F6-5F531EF05BAFQ47143452-49ED0786-FDD4-4C55-81A3-8438DA35DE81Q47193084-5C3E0A55-1A04-4F7B-9275-86C378D72B04Q47332302-2C03EF82-548C-4503-A70A-8F14CE014DA9Q47443248-E72117BE-D720-4C18-913F-2747EC1999E0Q47691629-7963AF63-AD6D-44FF-85A7-7397FAF94569Q49843607-A87316F9-D582-4D5D-A279-925C117ED2A4Q51023212-329110E1-8CFD-4E2E-8A4F-7FC6F81F632CQ53739786-38219A36-415B-4C53-80F6-FB1B1AFA6DC1Q57044372-83B1E3A3-1C53-4E33-9298-23FE2AA9E7F6Q58776633-F130AD1A-0776-4D0C-9AA7-11FF8AF38AB9Q58804389-9E8015E8-7F51-4263-8E23-E4C5AEB1D6EF
P2860
Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 October 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Mutational landscape of EGFR-, ...... models of lung adenocarcinoma.
@en
Mutational landscape of EGFR-, ...... models of lung adenocarcinoma.
@nl
type
label
Mutational landscape of EGFR-, ...... models of lung adenocarcinoma.
@en
Mutational landscape of EGFR-, ...... models of lung adenocarcinoma.
@nl
prefLabel
Mutational landscape of EGFR-, ...... models of lung adenocarcinoma.
@en
Mutational landscape of EGFR-, ...... models of lung adenocarcinoma.
@nl
P2093
P2860
P50
P356
P1476
Mutational landscape of EGFR-, ...... models of lung adenocarcinoma.
@en
P2093
Adam P Rosebrock
Arjun Bhutkar
David G McFadden
Emily Hodges
Frances K Chen
James T Platt
Mono Pirun
Nicholas D Socci
Philip M Santiago
P2860
P304
E6409-E6417
P356
10.1073/PNAS.1613601113
P407
P577
2016-10-04T00:00:00Z